MEDULLARY THYROID CANCER
Clinical trials for MEDULLARY THYROID CANCER explained in plain language.
Never miss a new study
Get alerted when new MEDULLARY THYROID CANCER trials appear
Sign up with your email to follow new studies for MEDULLARY THYROID CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill targets hard-to-treat cancers with RET gene mutations
Disease control OngoingThis study tests an oral drug called selpercatinib in people with advanced solid tumors that have a specific RET gene change. The goal is to see if the drug is safe and can shrink tumors. About 857 adults with lung, thyroid, colon, or other cancers took part. The drug is taken by…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New pill shows promise against rare childhood cancers
Disease control OngoingThis study tests an oral drug called LOXO 292 in 36 children with advanced solid or brain tumors that have a specific genetic change (RET alteration). The goal is to see if the drug can shrink tumors and control the disease. Participants must have already tried standard treatment…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 19, 2026 11:49 UTC
-
New pill shrinks tumors in patients with rare gene mutations
Disease control OngoingThis study tests an oral drug called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with a specific RET gene change. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the pill daily, and doctors …
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
Could a lower dose of this cancer drug be just as effective?
Disease control OngoingThis study tests whether a lower dose (60 mg) of the drug cabozantinib works as well as a higher dose (140 mg) in people with advanced medullary thyroid cancer that has spread. The goal is to see if the lower dose can control the cancer just as long while causing fewer side effec…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE4 • Sponsor: Exelixis • Aim: Disease control
Last updated May 18, 2026 11:59 UTC
-
New drug shows promise in slowing rare thyroid cancer
Disease control OngoingThis study tests whether a new drug called selpercatinib works better than standard treatments for people with a rare type of thyroid cancer (medullary thyroid cancer) that has a specific gene change (RET mutation) and has spread or cannot be removed by surgery. About 291 adults …
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated May 08, 2026 12:03 UTC